Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories
- 12 Aug 2019 Results of post-hoc analysis assessing disease duration and DMARDs affecting response by using data from two studies including this study published in the Annals of the Rheumatic Diseases.
- 16 Jun 2018 Results of pooled analysis (DE009, DE011, DE019, M10-261 and M13-390) presented at the 19th Annual Congress of the European League Against Rheumatism
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.